IMMUNOTECH-B (06978) announced that as of 4:00 PM on Tuesday, November 4, 2025 (the deadline for accepting rights shares and paying subscription fees, as well as applying for additional rights shares and making payments): (i) valid acceptances were received for 92.1758 million rights shares under 13 provisional allotment letters, representing approximately 89.56% of the 103 million rights shares offered; and (ii) valid applications were received for 446 million additional rights shares under 8 excess application forms, representing approximately 433.15% of the total 103 million rights shares offered.

In total, 21 valid acceptances and applications for 538 million rights shares were received, representing an oversubscription rate of approximately 522.71% relative to the 103 million rights shares offered. Among these, 435 million rights shares were oversubscribed, accounting for approximately 422.71% of the total offering.

The allocation of additional rights shares was conducted in accordance with the principles outlined in the "Application for Excess Rights Shares" section of the rights issue prospectus. Given that the number of excess rights shares available under the excess application forms was insufficient to fulfill all valid applications, 10.741 million rights shares were allocated to eligible shareholders applying for excess shares at a ratio of approximately 2.41% based on the number of excess shares requested per application.

No consideration was given to the number of rights shares applied for under provisional allotment letters or the current shareholdings of eligible shareholders, and no priority was given to applications seeking to round up odd lots into board lots.